SZSE:002589 (China)
Â
Class A
Â¥
3.53
(+2.32%)
Dec 12
Business Description
Realcan Pharmaceutical Group Co Ltd
NAICS : 325412
ISIN : CNE1000013X5
Share Class Description:
SZSE:002589: Class ACompare
Compare
Traded in other countries / regions
002589.China IPO Date
2011-06-10Description
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.67 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.28 | |||||
| Debt-to-EBITDA | 69.49 | |||||
| Interest Coverage | 0.28 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.93 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -34.2 | |||||
| 3-Year EBITDA Growth Rate | -40.7 | |||||
| 3-Year FCF Growth Rate | 2.7 | |||||
| 3-Year Book Growth Rate | -10 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.55 | |||||
| 9-Day RSI | 64.67 | |||||
| 14-Day RSI | 61.36 | |||||
| 3-1 Month Momentum % | 43.64 | |||||
| 6-1 Month Momentum % | 43.64 | |||||
| 12-1 Month Momentum % | -2.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.14 | |||||
| Quick Ratio | 1.05 | |||||
| Cash Ratio | 0.46 | |||||
| Days Inventory | 47.79 | |||||
| Days Sales Outstanding | 178.36 | |||||
| Days Payable | 222.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.6 | |||||
| Dividend Payout Ratio | 0.48 | |||||
| Forward Dividend Yield % | 0.6 | |||||
| 5-Year Yield-on-Cost % | 0.6 | |||||
| Shareholder Yield % | -33.78 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 10.01 | |||||
| Operating Margin % | 0.79 | |||||
| Net Margin % | 0.5 | |||||
| FCF Margin % | -6.82 | |||||
| ROE % | 0.73 | |||||
| ROA % | 0.24 | |||||
| ROIC % | -0.27 | |||||
| 3-Year ROIIC % | 25.69 | |||||
| ROC (Joel Greenblatt) % | 3.39 | |||||
| ROCE % | 1.68 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 127.41 | |||||
| Shiller PE Ratio | 64.43 | |||||
| PS Ratio | 0.65 | |||||
| PB Ratio | 0.94 | |||||
| Price-to-Tangible-Book | 1.07 | |||||
| EV-to-EBIT | 74.91 | |||||
| EV-to-EBITDA | 74.91 | |||||
| EV-to-Revenue | 0.96 | |||||
| EV-to-FCF | -13.48 | |||||
| Price-to-GF-Value | 1.51 | |||||
| Price-to-Projected-FCF | 0.59 | |||||
| Price-to-Median-PS-Value | 1.36 | |||||
| Price-to-Net-Current-Asset-Value | 8.21 | |||||
| Earnings Yield (Greenblatt) % | 1.33 | |||||
| FCF Yield % | -10.23 | |||||
| Forward Rate of Return (Yacktman) % | -27.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Realcan Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 7,985.499 | ||
| EPS (TTM) (Â¥) | 0.027 | ||
| Beta | 0.6 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 41.53 | ||
| 14-Day RSI | 61.36 | ||
| 14-Day ATR (Â¥) | 0.140265 | ||
| 20-Day SMA (Â¥) | 3.2465 | ||
| 12-1 Month Momentum % | -2.87 | ||
| 52-Week Range (Â¥) | 2.05 - 3.67 | ||
| Shares Outstanding (Mil) | 1,504.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Realcan Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Realcan Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Realcan Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Realcan Pharmaceutical Group Co Ltd(SZSE:002589)'s stock price today?
The current price of SZSE:002589 is ¥3.53. The 52 week high of SZSE:002589 is ¥3.67 and 52 week low is ¥2.05.
When is next earnings date of Realcan Pharmaceutical Group Co Ltd(SZSE:002589)?
The next earnings date of Realcan Pharmaceutical Group Co Ltd(SZSE:002589) is .
Does Realcan Pharmaceutical Group Co Ltd(SZSE:002589) pay dividends? If so, how much?
The Dividend Yield %  of Realcan Pharmaceutical Group Co Ltd(SZSE:002589) is 0.6% (As of Today), Highest Dividend Payout Ratio of Realcan Pharmaceutical Group Co Ltd(SZSE:002589) was 0.48. The lowest was 0.05. And the median was 0.08. The  Forward Dividend Yield % of Realcan Pharmaceutical Group Co Ltd(SZSE:002589) is 0.6%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers